Aethlon Medical Comprehensive Income 2012-2025 | AEMD
Aethlon Medical comprehensive income from 2012 to 2025. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
|
Aethlon Medical Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2025 | $0 |
| 2024 | $0 |
| 2023 | $0 |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
| 2013 | |
| 2012 | |
|
Aethlon Medical Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2025-12-31 | $0 |
| 2025-09-30 | $0 |
| 2025-06-30 | $0 |
| 2025-03-31 | $0 |
| 2024-12-31 | $0 |
| 2024-09-30 | $0 |
| 2024-06-30 | $0 |
| 2024-03-31 | $0 |
| 2023-12-31 | $0 |
| 2023-09-30 | $0 |
| 2023-06-30 | $0 |
| 2023-03-31 | $0 |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | |
| 2018-09-30 | |
| 2018-06-30 | |
| 2018-03-31 | |
| 2017-12-31 | |
| 2017-09-30 | |
| 2017-06-30 | |
| 2017-03-31 | |
| 2016-12-31 | |
| 2016-09-30 | |
| 2016-06-30 | |
| 2016-03-31 | |
| 2015-12-31 | |
| 2015-09-30 | |
| 2015-06-30 | |
| 2015-03-31 | |
| 2014-12-31 | |
| 2014-09-30 | |
| 2014-06-30 | |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Health Maintenance Organizations | $0.003B | $0.000B |
| Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UnitedHealth Group (UNH) | United States | $276.233B | 18.66 |
| Cigna Group (CI) | United States | $71.482B | 9.09 |
| Humana (HUM) | United States | $23.068B | 11.22 |
| Centene (CNC) | United States | $18.343B | 18.19 |
| Molina Healthcare (MOH) | United States | $7.599B | 13.70 |
| Select Medical Holdings (SEM) | United States | $2.030B | 14.23 |
| Joint (JYNT) | United States | $0.125B | 0.00 |